A Study to Assess the Effect of ASP1585 on Pharmacokinetics of Valsartan in Healthy Volunteers

• Status: Completed
• Trial end date: 2010-04-01
• Target enrollment: 0
• Participant gender: Male

Summary

This study is to assess the effect of ASP1585 on pharmacokinetics of valsartan in 2x2 crossover method

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Astellas Pharma Inc
• Treatments: Valsartan

Criteria

Inclusion Criteria:

• Body weight: =<50.0kg, <80.0kg

• Body mass index: =<17.6, <26.4

• Healthy as judged by investigator or caregiver from subjective and objective symptoms and physical examination data

Exclusion Criteria:

• Attending another clinical trial within 120 days before the study

• Blood donation within 90 days (400ml) or 30 days (200ml) before the study

• Receiving any drugs within 7 days before the study

• History of allergy to drugs

• Having GI disorders

• History or complication of liver diseases

• History or complication of heart disease

• History or complication of respiratory diseases

• History or complication of renal diseases

• History or complication of cerebrovascular diseases